Design, Synthesis, and Mechanistic Evaluation of l-Theanine Derivatives Targeting Cathepsin D for Anti-Hepatic...

Area of Science:

• Pharmacology
• Hepatology
• Medicinal Chemistry

Background:

• Hepatic fibrosis is a significant global health issue with limited treatment options.
• Developing effective antifibrotic therapies is a critical unmet medical need.

Purpose of the Study:

• To synthesize and evaluate l-theanine derivatives as potential antifibrotic agents.
• To identify a novel compound with potent therapeutic effects against liver fibrosis.

Main Methods:

• Systematic structural modification of l-theanine to generate 40 derivatives.
• In vitro assays using hepatic stellate cells (LX-2 and mHSC) stimulated with TGFβ1.
• In vivo studies using rat bile duct ligation (BDL) and mouse methionine-choline-deficient high-fat diet (CDAHFD) models of liver fibrosis.
• Mechanistic studies involving Cathepsin D interaction and gene expression analysis.
• Pharmacokinetic evaluation of compound 9a and its metabolites.

Main Results:

• Compound 9a demonstrated potent dose-dependent inhibition of TGFβ1-induced hepatic stellate cell activation.
• In vivo, compound 9a significantly reduced hepatic injury, fibrosis, and inflammation in both BDL and CDAHFD models.
• Mechanistic studies revealed that compound 9a targets Cathepsin D, leading to its degradation and suppression of fibrogenic/inflammatory genes.
• Pharmacokinetic analysis identified active metabolites 10 and 11c formed from compound 9a.

Conclusions:

• Compound 9a is a highly effective antifibrotic agent derived from l-theanine.
• Compound 9a exhibits significant hepatoprotective effects and warrants further investigation for hepatic fibrosis treatment.
• Targeting Cathepsin D degradation represents a novel therapeutic strategy for liver fibrosis.